Results 171 to 180 of about 50,964 (281)

Far-infrared rays control prostate cancer cells _in vitro_ and _in vivo_

, 2008
We introduce a new effective method to control hormone refractory prostate cancer cells by using an activated rubber/resin form (RB), far-infrared ray emitter, with or without sodium butyrate (SB).
Mayumi Shincho, Jun Qiu, Yoshie Yoshikawa, Reigetsu Yoshikawa, Tomoko Hashimoto-Tamaoki, Hiroki Shima, Seiichi Hirota, Shingo Yamamoto   +7 more
core  

Undifferentiated Castration-Resistant Prostate Cancer Successfully Treated With Carboplatin and Paclitaxel. [PDF]

Case Rep Urol
Sano M, Shimbo M, Ohgita S, Kanomata N, Hattori K, Endo F.   +5 more
europepmc   +1 more source

Combining radiotherapy with CAR‐T cell therapy for solid tumors: Challenges, mechanisms, and future directions

Precision Radiation Oncology, Volume 10, Issue 2, Page 192-204, June 2026.
Radiotherapy enhances CAR‐Tcell therapy by increasing antigenicity, improving trafficking, and reshaping the tumor microenvironment. Despite its dual effects, including potential immune suppression, understanding these mechanisms enables the development of strategies to maximize synergy in solid tumors.
Leran Qiu, Xingyu Zhou, Jiao Xue, Xiaokang Zhang, Songbing Qin   +4 more
wiley   +1 more source

Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer.

Therapies that abrogate persistent androgen receptor (AR) signaling in castration-resistant prostate cancer (CRPC) remain an unmet clinical need.
Mateos, B, Crespo, M, Jung, N, Sharp, A, Rekowski, J, Plymate, SR, Swain, A, Carreira, S, Nava Rodrigues, D, de Bono, JS, Ning, J, Gurel, B, Lee, II, Al-Lazikani, B, Jiménez-Vacas, JM, Seeger, R, Cato, ACB, Yuan, W, Cato, L, Jiang, Y, Neeb, A, Muhle-Goll, C, Salvatella, X, Ferreira, A, Riisnaes, R, Bogdan, D, Di Micco, P, Bielskutė, S, Qiu, X, Miranda, S, Buroni, L, Bräse, S, Figueiredo, I, Gräßle, S, Welti, J, Gourain, V, Long, HW, Brown, M, Stober, J   +38 more
core   +1 more source

A new perspective on radiotherapy in the comprehensive treatment of cancer

Precision Radiation Oncology, Volume 10, Issue 2, Page 165-183, June 2026.
Radiotherapy remains a key component in the comprehensive management of cancer. Its effectiveness is significantly improved through strategic combinations with chemotherapy, targeted therapy, and immunotherapy, providing a range of therapeutic outcomes from cure to palliative care.
Yingze Ma, Hongxuan Yu, Shijie Shang, Shixin Shan, Dawei Chen   +4 more
wiley   +1 more source

PARP Inhibition in Castration-Resistant Prostate Cancer [PDF]

Future Oncology, 2016
Lucia, Nappi, Martin E, Gleave
openaire   +2 more sources

Investigation of the role of t(4;6) and 6q15 deletion in prostate cancer development and progression

, 2010
PhDThe recent identification of TMPRSS2:ETS gene fusions highlighted the importance of chromosomal rearrangement and fusion gene development in prostate tumourigenesis.
Shan, Ling
core  

Erratum: [Corrigendum] Inhibition of Rac1 reverses enzalutamide resistance in castration-resistant prostate cancer. [PDF]

Oncol Lett
Chen X, Yin L, Qiao G, Li Y, Li B, Bai Y, Feng F.   +6 more
europepmc   +1 more source

The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone‐Sensitive Prostate Cancer Treated With First‐Line ARPI Therapy

The Prostate, Volume 86, Issue 8, Page 882-890, June 2026.
ABSTRACT Background Radiographic progression (RP) without prostate‐specific antigen (PSA) elevation has emerged as a clinically important pattern in the androgen receptor pathway inhibitors (ARPI) era, but its prevalence and prognostic significance in real‐world metastatic hormone‐sensitive prostate cancer (mHSPC) cohorts remain unclear.
Takeshi Tsutsumi, Shogo Yamazaki, Takuya Matsuda, Takuya Tsujino, Taizo Uchimoto, Takafumi Yanagisawa, Keiichiro Mori, Wataru Fukuokaya, Fumihiko Urabe, Masanobu Saruta, Atsuhiko Yoshizawa, Shingo Toyoda, Saizo Fujimoto, Kyosuke Nishio, Moritoshi Sakamoto, Tatsuo Fukushima, Ko Nakamura, Kazuki Nishimura, Keita Nakamori, Tomohisa Matsunaga, Yuki Yoshikawa, Ryoichi Maenosono, Kiyoshi Takahara, Teruo Inamoto, Takahiro Kimura, Kazutoshi Fujita, Kazumasa Komura, Haruhito Azuma   +27 more
wiley   +1 more source

Androgen receptor reactivation in castration-resistant prostate cancer: mechanisms, epigenetic adaptation, and therapeutic vulnerabilities. [PDF]

Front Oncol
Guo J, Wu K, Ma Z, Guo S, Wang F, Lu L.
europepmc   +1 more source